Study Findings from University of North Carolina Provide New Insights into Fusion Proteins (Tetraspecific ligand for tumor-targeted delivery of nanomaterials)
By a News Reporter-Staff News Editor at Cancer Weekly -- Researchers detail new data in Fusion Proteins. According to news reporting from Chapel Hill, North Carolina, by NewsRx journalists, research stated, "The polygenetic nature of most cancers emphasizes the necessity of cancer therapies that target multiple essential signaling pathways. However, there is a significant paucity of targeting ligands with multispecificities for targeted delivery of biomaterials."
The news correspondents obtained a quote from the research from the University of North Carolina, "To address this unmet need, we generated a tetraspecific targeting ligand that recognizes four different cancer biomarkers, including VEGFR2, alpha(v)beta(3) integrin, EGFR, and HER2 receptors, which have been implicated in numerous malignant tumors. The tetraspecific targeting ligand was constructed by sequentially connecting four targeting ligand subunits via flexible linkers, yielding a fusion protein that can be highly expressed in Escherichia coli and readily purified to near homogeneity. Surface Plasmon Resonance (SPR), Bio-Layer Interferometry (BLI) studies and extensive cellular binding analyses indicated that all the targeting ligand subunits in the tetraspecific fusion protein recognized their target receptors proximately to the corresponding monospecific ligands. The resulting tetraspecific targeting ligand was applied for the delivery of nanomaterials such as gold nanoparticles (AuNPs) for targeted hyperthermic killing of various cancer cell lines with biomarkers of interest expressed. We demonstrate that the tetraspecific ligand can be facilely introduced on the surface of AuNPs and efficient target-dependent killing of cancer cells can be achieved only when the AuNPs are conjugated with the tetraspecific ligand. Significantly, the tetraspecific ligand simultaneously interacts with more than one receptors, such as EGFR and HER2 receptors, when they are expressed on the surface of the same cell, as demonstrated by in vitro binding assays and cell binding analyses."
According to the news reporters, the research concluded: "Our results demonstrate that the tetraspecific ligand, through multivalency and synergistic binding, can be readily used to generate various 'smart' biomaterials with greatly broadened tumor targeting range for simultaneous targeting of multiple signaling pathways on many different cancer types."
For more information on this research see: Tetraspecific ligand for tumor-targeted delivery of nanomaterials. Biomaterials, 2014;35(23):6026-6036. Biomaterials can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)
Our news journalists report that additional information may be obtained by contacting D. Kim, University of North Carolina, Carolina Center Genome Sci, Chapel Hill, NC 27599, United States. Additional authors for this research include A.D. Friedman and R. Liu (see also Fusion Proteins).
Keywords for this news article include: Cancer, Oncology, Chapel Hill, Nanomaterial, United States, North Carolina, Nanotechnology, Fusion Proteins, Emerging Technologies, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC